Q1 FY 20 Performance Update

Six spaces which will drive significant growth 1 US Generics 107 products pending approval in US* Ramp-up in New launches Providing great customer service We have a healthy pipeline of First-to-market, complex Products NUMBER OF PENDING FILINGS* BY DOSAGE FORM Topical/ Transdermal/ Inhalation, 1 Softgel, 2 Complex Inj/ Sterile, 19 Vaginal, 8 OSD, 41 10 products launched in the US during the FY 20 so far • PIPELINE HIGHLIGHTS 104 pending ANDAs & 3 pending NDAS [505(b)(2)s] No incl. 58 para-IV and we believe 34 have first to file status Injectable, 15 Complex OSD, 21 Filings as of June 30, 2019 Fast-following on potential OTC switches PROPRIETARY

View entire presentation